Can Ajanta Pharma Sustain Its Earnings Momentum?

Jefferies has maintained a Buy rating on Ajanta Pharma with a revised target price of ₹3,120 (earlier ₹3,320), following a stronger-than-expected Q2FY26 performance adjusted for forex impact. The brokerage expects continued strength in the US and African markets, projecting FY26 EBITDA margins at around 27% due to sustained product momentum.

Can Ajanta Pharma Sustain Its Earnings Momentum After Jefferies’ Positive Q2FY26 Review?

About Ajanta Pharma

Ajanta Pharma Ltd continues to deliver consistent growth across key markets in India, Africa, and the US. Jefferies reiterated its Buy rating, recognizing Ajanta’s strong execution in specialty segments and robust export performance. The company’s diversified product mix, particularly in branded generics, has supported steady growth and high margins despite currency headwinds.

Jefferies highlighted that Ajanta’s Q2FY26 EBITDA margin remained resilient at 27%, even as forex adjustments impacted reported earnings. The company’s US and African markets contributed significantly to growth, with strong sales traction in ophthalmology, dermatology, and cardiology portfolios.

Financial Highlights (Q2 FY26)

Metric	Q2 FY26	YoY
Revenue	₹1,020 Cr	+10%
EBITDA	₹275 Cr	+13%
EBITDA Margin	27%	Stable
PAT	₹205 Cr	+9%

Revenue ₹1,020 Cr saw 10% YoY growth, aided by higher exports and steady India sales. EBITDA ₹275 Cr increased by 13% due to product mix improvement and operating efficiency. Margins at 27% remained firm, underscoring Ajanta’s disciplined cost structure. PAT ₹205 Cr improved on strong demand in Asia and Africa despite forex volatility.

Stay informed with the most recent Nifty Trading Tips tailored for pharma and healthcare stocks to align positions with market sentiment.

Peer Comparison

Company	EBITDA Margin	YoY Growth
Ajanta Pharma	27%	+10%
Alkem Labs	22%	+9%
Cipla	24%	+8%

SWOT Analysis

Strengths ✅ Strong export presence in US, Africa, and Asia. ✅ Robust portfolio in chronic therapies and branded generics.

Weaknesses ⚠️ Forex fluctuations impacting quarterly profitability. ⚠️ Limited domestic market share in select categories.

Opportunities 💡 Expanding presence in US generics and Africa markets. 💡 New product launches in ophthalmology and cardiology segments.

Threats 📉 Regulatory tightening in export markets. 📉 Currency volatility impacting export margins.

Use specialized Bank Nifty Trading Tips to track institutional sentiment in healthcare-driven markets and plan entry-exit levels accordingly.

Valuation & Investment View

• Short-term: Supported by strong exports and product demand recovery.
• Medium-term: Increased Africa sales and new launches to drive growth.
• Long-term: Sustained R&D focus and high-margin generics to ensure profitability.

Investor Takeaway

Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, highlights that Ajanta’s strong exports, cost control, and new product pipeline keep it well-positioned. Explore more market insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.

Related Queries on Ajanta Pharma

• How did Ajanta Pharma manage 27% EBITDA margins in Q2FY26?
• What are Jefferies’ key drivers behind its Buy rating on Ajanta?
• Can African markets sustain Ajanta’s export-led growth trajectory?

SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.

Ajanta Pharma, Jefferies Report, Q2 FY26, EBITDA 27%, Buy Rating, Nifty Trading Tips, Bank Nifty Trading Tips, Gulshan Khera CFP